Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response

BACKGROUND: Radium-223 is a bone-seeking, ɑ-emitting radionuclide used to treat men with bone metastases from castration-resistant prostate cancer. Sclerotic bone lesions cannot be evaluated using Response Evaluation Criteria in Solid Tumors. Therefore, imaging response biomarkers are needed. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Parker, Chris, Tunariu, Nina, Tovey, Holly, Alonzi, Roberto, Blackledge, Matthew D, Cook, Gary J R, Chua, Sue, Du, Yong, Hafeez, Shaista, Murray, Iain, Padhani, Anwar R, Staffurth, John, Tree, Alison, Stidwill, Helen, Finch, Jessica, Curcean, Andra, Chatfield, Peter, Perry, Sophie, Koh, Dow-Mu, Hall, Emma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640884/
https://www.ncbi.nlm.nih.gov/pubmed/37788117
http://dx.doi.org/10.1093/jncics/pkad077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640884/
https://www.ncbi.nlm.nih.gov/pubmed/37788117
http://dx.doi.org/10.1093/jncics/pkad077

Ejemplares similares